Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02301429
Other study ID # LV DDD
Secondary ID
Status Active, not recruiting
Phase N/A
First received October 20, 2014
Last updated June 27, 2016
Start date November 2014
Est. completion date July 2016

Study information

Verified date December 2015
Source Medtronic BRC
Contact n/a
Is FDA regulated No
Health authority South Africa: Human Research Ethics CommitteeCanada: Health CanadaSingapore: Institutional Review BoardThe Netherlands: Medical Ethics Review Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the implant procedure and feasibility of a new lead developed to pace and sense the left chambers of the heart.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 16
Est. completion date July 2016
Est. primary completion date July 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subject has Cardiac pacing indication for sinus node dysfunction (dual chamber pacemaker)

- Subject has signed and dated the study-specific informed consent form

- Subject is 18 years of age or older

- Subject is willing, able and committed to participate in Baseline and Follow-up and study procedures for the full length of the study

Exclusion Criteria:

- Subject is indicated for BiV pacemaker or ICD

- Subject is pacing dependent

- Subject has a previous Pacemaker System

- Subject has known coronary venous vasculature that is inadequate for lead placement

- Subject has unstable angina pectoris or has had an acute myocardial infarction (MI) within the last month

- Subject has had a coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the past three months

- Subject is not in sinus rhythm at implant

- Subject has had a heart transplant (patients waiting for heart transplants are allowed in the study)

- Subject has known renal insufficiency that would prevent them from receiving an occlusive venogram during the implant procedure

- Subject is contraindicated for <1mg dexamethasone acetate

- Subject is enrolled in any concurrent drug and/or device study that may confound the results of this study

- Subject has a terminal illness and is not expected to survive more than 6 months

- Subject is a pregnant woman or woman of childbearing potential not on adequate birth control.

- Subject is employed by Medtronic or by the department of any of the investigators or is a close relative of any of the investigators.

- Legal incapacity or evidence that a subject cannot understand the purpose and risks of the study

- Subject meets exclusion criteria required by local law.

- Subject is unable to tolerate an urgent thoracotomy

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Model 20105
implant and follow-up of study device

Locations

Country Name City State
Canada London Teaching Hospital London
Netherlands Reinier de Graaf Hospital Delft
Singapore NUHCS, National University Hospital Singapore
South Africa Milpark hospital Johannesburg

Sponsors (1)

Lead Sponsor Collaborator
Medtronic BRC

Countries where clinical trial is conducted

Canada,  Netherlands,  Singapore,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary All Implant procedure and lead related adverse events will be collected during the first month post implant and analyzed. All Implant procedure and lead related adverse events will be collected during the first month post implant and analyzed. 1 month Yes